Biofrontera AG: Announcement for Announcements of holders of considerable holdings according to article 43 WpHG

Heidelberg, Germany (pta021/13.11.2024/13:46 UTC+1) - Release of Release according to § 43 WpHG

Notification of Major Holdings

Notification of Holdings

In a letter dated November 11, 2024, received on the same day, Biofrontera AG received the following notification on behalf of Deutsche Balaton Biotech AG pursuant to section 43 (1) WpHG (German Securities Trading Act):


“Notification of objectives of holders of significant shareholdings in the company pursuant to Section 43 (1) WpHG:We refer to the voting rights notification of Mr. Wilhelm Zours dated November 11, which shows the direct participation of our company in Biofrontera AG of more than 10% of the voting rights. A. Objectives pursued with the acquisition of voting rights: 1. The investment of Deutsche Balaton Biotech AG is long-term and is made with the purpose of achieving capital growth. To this end, we expect that patience over a medium time horizon will be useful.2. Deutsche Balaton Biotech AG does not currently intend, but does not rule out the possibility of acquiring further voting rights directly or indirectly within the next twelve months. Depending on the price, further voting rights could be acquired within the next twelve months by purchase or otherwise.3 Deutsche Balaton Biotech AG is currently not seeking to exert any influence on the composition of the Supervisory Board of Biofrontera AG. At present, it is intended to retain these personnel. However, we intend to exercise our voting rights at our discretion in the next elections of Supervisory Board members. 4) Deutsche Balaton Biotech does not intend to significantly change the capital structure of the company (in particular with regard to the ratio of equity and debt financing and the dividend policy).
B. With regard to the origin of the funds for the acquisition of the voting rights in Biofrontera AG, we inform you that Deutsche Balaton Biotech AG used its own funds for the acquisition of the voting rights it acquired directly in Biofrontera AG.”

(end)